Reducing the incidence of non-A,non-B post-transfusion hepatitis by testing donor blood for alanine aminotransferase: economic considerations.

Abstract

Recent studies have established a relation between elevated alanine aminotransferase levels in donor blood and the incidence of non-A, non-B hepatitis in recipients of such blood. Routine testing of donor blood for alanine aminotransferase activity in order to reduce hepatitis is not currently supported, largely because the results of such testing are unknown. We assessed the potential economic benefits of screening donor blood for alanine aminotransferase as a means to reduce post-transfusion hepatitis. Benefits, defined as the expected costs of hepatitis potentially avoided, ranged from $898 to $31,629 per 1000 blood units collected. This wide range reflected lack of information about the natural history of non-A, non-B hepatitis. Costs were defined as the direct costs of testing and the indirect costs associated with loss of blood product, additional donor recruitment, and informing donors of their abnormal aminotransferase levels; costs ranged from $3,151 to $4,003 per 1000 units. Our results suggest that if prospective studies demonstrate that exclusion of blood with elevated aminotransferase levels decreases non-A, non-B hepatitis in recipients, the net economic impact may be positive. However, because of major uncertainties about the medical consequences of non-A, non-B hepatitis, the benefit estimates are so broad that they preclude a definitive policy decision.